Position for potential upside ahead of Phase 3 topline data in H2 2026; monitor for signs of commercial preparation and regulatory engagement. The strong efficacy and safety profile support brelovitug as a best-in-class candidate in HDV, a space with high unmet need.
MIRM drugs
MIRM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $92.48entry
- T+1 · 7mo ago +1.64%α +2.13% · $94.00
- T+5 · 7mo ago +14.39%α +13.99% · $105.79
- T+20 · 6mo ago +6.94%α +1.99% · $98.90
- T+60 · 4mo ago +23.79%α +19.01% · $114.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mirum Pharmaceuticals announced positive Phase 2b results for brelovitug in treating chronic hepatitis delta virus (HDV), with 100% and 75% virologic response rates in the two dose groups versus 0% in the control. The drug was well tolerated, supporting its potential as a single-agent therapy and advancing the program toward Phase 3 topline data in H2 2026.
Key Facts
- Brelovitug met primary endpoint in Phase 2b AZURE-1 study for chronic HDV treatment
- 100% of patients in 300 mg QW arm and 75% in 900 mg Q4W arm achieved virologic response vs. 0% in delayed treatment arm
- Primary composite endpoint (virologic response + ALT normalization) achieved in 45% and 35% of patients, respectively
- Treatment was well tolerated with no grade 3+ treatment-related adverse events and no discontinuations due to AEs
- Full results to be presented at EASL Congress in May 2026; Phase 3 topline data expected in H2 2026, with potential BLA submission and U.S. launch in 2027
Financial Impact
Significant positive impact on valuation potential; drug advancement reduces development risk for a high-unmet-need indication with no approved therapies
Risk Factors
- Phase 3 results may not replicate Phase 2b efficacy
- Regulatory requirements may exceed current expectations
- Competition could emerge before 2027 launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179048 |
| Document: 0001193125-26-179048-index-headers.html | 0001193125-26-179048 |
| Document: 0001193125-26-179048-index.html | 0001193125-26-179048 |
| Document: 0001193125-26-179048.txt | 0001193125-26-179048 |
Track record
27 reports on MIRM
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers